Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor

Clinical Cancer Research

Volumn 10, Issue 12 I, 2004, Pages 4038-4047

  Maquoi, Erik ^a   Sounni, Nor Eddine ^a   Devy, Laetitia ^a   Olivier, Fabrice ^a   Frankenne, Francis ^a   Krell, Hans Willi ^b   Grams, Frank ^c   Foidart, Jean Michel ^a   Noël, Agnès ^a,d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; GELATINASE A; GELATINASE B; GI 129471; MARIMASTAT; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; PYRIMIDINE 2,4,6 TRIONE DERIVATIVE; RO 28 2653; SELECTIVE MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CHEMOINVASION ASSAY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AORTA; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MICROSCOPY, FLUORESCENCE; MODELS, CHEMICAL; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHENYLALANINE; PIPERAZINES; PROTEASE INHIBITORS; PYRIMIDINES; RATS; THIOPHENES; TIME FACTORS; UP-REGULATION;

EID: 3042526364     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0125     Document Type: Article

References (52)

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
3. Woessner JF. The matrix metalloproteinase family. In: Parks WC and Mecham RP, editors. Matrix metalloproteinases. San Diego, CA, Academic Press; 1998. p. 1-14.
4. Maquoi E, Munaut C, Colige A, Collen D, Lijnen HR. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002;51:1093-101.
5. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
6. Noël A, Emonard H, Polette M, Birembaut P, Foidart JM. Role of matrix, fibroblasts and type IV collagenases in tumor progression and invasion. Pathol Res Pract 1994;190:934-41.
7. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (Lond) 1990;348:699-704.
8. Bisson C, Blacher S, Polette M, et al. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer 2003;105:7-13.
9. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Investig New Drugs 1997;15:61-75.
10. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst (Bethesda) 2001;93:178-93.
11. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19:6642-50.
12. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash DC) 2002;295:2387-92.
13. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 2003;7:385-97.
14. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51.
15. Della Porta P, Soeltl R, Krell HW, et al. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. Anticancer Res 1999;19:3809-16.
16. Krüger A, Soeltl R, Sopov I, et al. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 2001;61:1272-5.
17. Drummond AH, Beckett P, Brown PD, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999;878:228-35.
18. Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 1998;80:907-8.
19. Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003;48:1742-9.
20. Gatto C, Rieppi M, Borsotti P, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999;5:3603-7.
21. Tamura Y, Watanabe F, Nakatani T, et al. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem 1998;41:640-9.
22. Katori H, Baba Y, Imagawa Y, et al. Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Lett 2002;178:151-9.
23. Yamamoto A, Yano S, Shiraga M, et al. A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int J Cancer 2003;103:822-8.
24. Grams F, Brandstetter H, D'Alo S, et al. Pyrimidine-2,4,6-triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol Chem 2001;382:1277-85.
25. Maquoi E, Frankenne F, Baramova E, et al, Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J Biol Chem 2000;275:11368-78.
26. Sounni NE, Baramova EN, Munaut C, et al. Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. Int J Cancer 2002;98:23-8.
27. McGeehan, G. M. Becherer JD, Bast RC, et al. Regulation of tumor necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (Lond) 1994;370:558-61. GI129471 (27), BB-94 (28) and BB-2516 (29).
28. Inventor: Campion C, Davidson JP, Dickens JP, Crimmin MJ. Assignee: British Biotechnology, Great Britain. Matrix metalloproteinase inhibitor BB-94. Patent Cooperation Treaty Patent Application, WO 90/05719, 5/31/90.
29. Inventor: Miller KM, Bawden LJ, Brown PD. Assignee: British Biotechnology, Great Britain. Matrix metalloproteinase inhibitor BB-2516. Patent WO 93/21942, 11/11/93.
30. Maquoi E, Noël A, Frankenne F, Angliker H, Murphy G, Foidart JM. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett 1998;424:262-6.
31. Noël A, Calle A, Emonard HP, et al. Invasion of reconstituted basement membrane matrix is not correlated to the malignant metastatic cell phenotype. Cancer Res 1991;51:405-14.
32. Noël A, De Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by Matrigel and fibroblasts. Br J Cancer 1993;68:909-15.
33. Noël A, Hajitou A, L'Hoir C, et al. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer 1998;76:267-73.
34. Blacher S, Devy L, Burbridge MF, et al. Improved quantification of angiogenesis in the rat aortic ring assay. Angiogenesis 2001;4:133-42.
35. Maquoi E, Munaut C, Colige A, et al. Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. Exp Cell Res 2002;275:110-21.
36. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
37. Yang W, Arii S, Gorrin-Rivas MJ, Mori A, Onodera H, Imamura M. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer (Phila) 2001;91:1277-83.
38. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252-7.
39. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
40. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
41. Van den Hooff A. Stromal involvement in malignant growth. Adv Cancer Res 1988;50:159-96.
42. Masson R, Lefebvre O, Noël A, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140:1535-41.
43. Huang S, Van Arsdall M, Tedjarati S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst (Bethesda) 2002;94:1134-42.
44. Sounni NE, Janssen M, Foidart JM, Noël A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003;22:55-61.
45. Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002;16:555-64.
46. Deryugina EI, Soroceanu L, Strongin AY. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res 2002;62:580-8.
47. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45.
48. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998;95:365-77.
49. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000;97:4052-7.
50. Sounni NE, Roghi C, Chabottaux V, et al. Up-regulation of VEGF-A by active MT1-MMP through activation of Src-tyrosine kinases. J Biol Chem 2004;279:13564-74.
51. Arlt M, Kopitz C, Pennington C, et al. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res 2002;62:5543-50.
52. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.